Canaccord Genuity Maintains Buy on Zevra Therapeutics, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Sumant Kulkarni maintains a Buy rating on Zevra Therapeutics (NASDAQ:ZVRA) and raises the price target from $19 to $20.
August 15, 2023 | 1:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Canaccord Genuity maintains a Buy rating on Zevra Therapeutics and raises the price target from $19 to $20.
The news is directly related to Zevra Therapeutics as Canaccord Genuity maintains a Buy rating on the company and raises the price target. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100